Prucalopride for constipation

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 3, 2010, Pages 451-461

  Camilleri, Michael ^a   Deiteren, Annemie ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

5 HT4 receptor; Efficacy; Enterokinetic; Pharmacodynamics; Pharmacokinetics; Prokinetic; R093887; R108512; Safety; Serotonin agonist

Indexed keywords

CISAPRIDE; CLEBOPRIDE; ERYTHROMYCIN; METOCLOPRAMIDE; MOSAPRIDE CITRATE; OPIATE; PLACEBO; PRUCALOPRIDE; R 108512; RENZAPRIDE; SEROTONIN 4 RECEPTOR; TEGASEROD; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CHRONIC DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GOVERNMENT REGULATION; HEART ARRHYTHMIA; HEART RATE; HUMAN; ILEUS; INTESTINE PSEUDOOBSTRUCTION; INTESTINE TRANSIT TIME; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; QT INTERVAL; REVIEW; SCLERODERMA; SIDE EFFECT; SPINAL CORD INJURY; TREATMENT WITHDRAWAL;

AGED; BENZOFURANS; CONSTIPATION; DEFECATION; GASTROINTESTINAL TRANSIT; HUMANS; LAXATIVES; SEROTONIN;

EID: 76449107222     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903567057     Document Type: Review

References (80)

1. Higgins P, Johanson J. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-759 (Pubitemid 38612817)
2. Bharucha A, Camilleri M, Haydock S, et al. Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut 2000;47:667-674
3. Shah N, Chitkara D, Locke G, et al. Ambulatory care for constipation in the United States, 1993 - 2004. Am J Gastroenterol 2008;103:1746-1753
4. Choung R, Locke GR, Schleck C, et al. Cumulative incidence of chronic constipation: a population-based study 1988 - 2003. Aliment Pharmacol Ther 2007;26:1521-1528
5. Johanson J, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25:599-608
6. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-1368
7. De Maeyer J, Ver Donck L, Heylen L, Schuurkes J. Prucalopride, the first representative of a new generation of highly selective 5-HT4 receptor agonists. UEGW. Paris: UEGF, 2007:OP-E-381
8. FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. FDA, Press Announcements. Washington, DC: FDA/News Events, 2009. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm149533.htm. [Last accessed 27 September 2009]
9. FDA Announces Discontinued Marketing of GI Drug, Zelnorm for Safety Reasons. FDA, Press Announcements. Washington, DC: FDA/News Events, 2007. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2007/ ucm108879.htm. [Last accessed 27 September 2009]
10. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99-112
11. Propulsid (cisapride) Dear Healthcare Professional Letter. FDA, Safety Information. Washington, DC: FDA/Safety, 2000. Available from: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm175000.htm. [Last accessed 27 September 2009]
12. Mohammad S, Zhou Z, Gong Q, January C. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997;273:H2534-8
13. Wysowski D, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-1703
14. Johanson J, Drossman D, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008 274:685-696
15. Johanson J, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-177
16. Hegde S, Eglen R. Peripheral 5-HT4 receptors. FASEB J 1996;10:1398-1407
17. Foxx-Orenstein A, Kuemmerle J, Grider J. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 1996;111:1281-1290
18. Briejer M, Bosmans J, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;423:71-83
19. De Maeyer JH, Prins NH, Schuurkes JA, Lefebvre RA. Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior. J Pharmacol Exp Ther 2006;317:955-964
20. Cellek S, Thangiah R, Jarvie EM, et al. Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. Neurogastroenterol Motil 2008;20:539-545
21. Prins N, Shankley N, Welsh N, et al. An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 2000;129:1601-1608
22. Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 2000;131:927-932
23. Prins N, Van Haselen J, Lefebvre R, et al. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999;127:1431-1437
24. Leclere PG, Prins NH, Schuurkes JA, Lefebvre RA. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil 2005;17:366-375
25. Cellek S, John A, Thangiah R, et al. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol Motil 2006;18:853-861
26. Prins N, van Der Grijn A, Lefebvre R, et al. 5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001;132:1941-1947
27. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001;13:465-472
28. Karaus M, Sarna S. Giant migrating contractions during defecation in the dog colon. Gastroenterology 1987;92:925-933
29. Bassotti G, Chiarioni G, Vantini I, et al. Anorectal manometric abnormalities and colonic propulsive impairment in patients with severe chronic idiopathic constipation. Dig Dis Sci 1994;39:1558-1564
30. Briejer M, Engelen M, Jacobs J, et al. R093877 enhances defecation frequency in conscious cats. Gastroenterology 1997;112:A705
31. Qi H, Luo J, Liu X. Effect of enterokinetic prucalopride on intestinal motility in fast rats. World J Gastroenterol 2003;9:2065-2067
32. De Winter B, Boeckxstaens G, De Man J, et al. Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut 1999;45:713-718
33. Briejer M, Meulemans A, Wellens A, Schuurkens J. R093877 dose-dependently accelerates gastric emptying in conscious dogs. Gastroenterology 1997;112:A705
34. Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor) in man. Gut 2008;57:A282
35. Van de Velde V, Ausma J, Vandeplassche L. Food does not affect the oral bioavailability of prucalopride. Gastroenterology 2008;134:A547
36. Investigator's brochure on prucalopride. Movetis NV, Turnhout, Belgium
37. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682-686
38. Vandeplassche G, Crabbé R, De Smedt H, et al. A placebo-controlled study to evaluate the effects of R093877 on bowel habit, safety and tolerability in healthy volunteers. Gastroenterology 1997;112:A843
39. Hagger R, Benson M, Lloyd R, et al. A placebo-controlled study to evaluate the effect on colonic transit of R093877 in healthy volunteers. Gastroenterology 1998;144:A759
40. Emmanuel A, Kamm M, Roy A, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998;42:511-516
41. Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999;13:1493-1497
42. De Schryver AM, Andriesse GI, Samsom M, et al. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002;16:603-612
43. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-360
44. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16:759-767
45. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347-1356
46. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82-89
47. Nichols T, Beyens G, Ausma J, et al. A double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of prucalopride in patients with chronic constipation. UEGW. Vienna 2008:P0894
48. Miner PJ, Nichols T, Silvers D, et al. The efficacy and safety of prucalopride in patients with chronic constipation. Gastroenterology 1999;116:A1043
49. Felt-Bersma R, Bouchoucha M, Wurzer H, et al. Effects of a new enterokinetic drug, prucalopride, on symptoms of patients with chronic constipation: a double-blind, placebo-controlled, multicenter study in Europe. Gastroenterology 1999;116:A1043
50. Winter H, Ausma J, Vandeplassche L. An open label follow-up study of prucalopride solution in pediatric subjects with functional fecal retention. Gastroenterology 2009;136:A129
51. Moulin D, Rykx A, Kerstens R, Vandeplassche L. Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor) in patients with opioid-induced constipation. Gastroenterology 2008;134:A92
52. Schuurkes J, Meulemans A, Briejer M, et al. The enterokinetic R093877 normalizes opioid-delayed fecal pellet propulsion in the isolated guinea-pig distal colon. Gastroenterology 1998;114:A835
53. Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002;37:431-436
54. Galandiuk S, Beyens G, Ausma J, Vandeplassche L. Evaluation of the efficacy, safety and tolerability of prucalopride (Resolor) given subcutaneously in patients undergoing elective partial colectomy. Gastroenterology 2008;134:A138
55. D'Hooghe B, Guillaum D, Medaer R, et al. Treatment of constipation in multiple sclerosis patients: pilot study with the novel enterokinetic prucalopride. Neurogastroenterol Motil 1999;11:A256
56. Kamm M, Emmanuel A, Kerstens R, Vandeplassche L. Double-blind, placebo-controlled, cross-over, multiple (n = 1) trial to evaluate the effects of prucalopride in patients with chronic intestinal pseudo-obstruction (CIP). UEGW. Vienna 2008:P0900
57. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 2002;97:194-197
58. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-2354
59. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-328
60. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-365
61. Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999;34:870-877
62. Marquis P, De La Loge C, Dubois D, et al. Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol 2005;40:540-551 (Pubitemid 40676247)
63. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004;2:796-805
64. Tack J, Middleton S, Horne M, et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1655-1665
65. Müller-Lissner S. Treatment of chronic constipation with cisapride and placebo. Gut 1987;28:1033-1038
66. Petticrew M, Rodgers M, Booth A. Effectiveness of laxatives in adults. Qual Health Care 2001;10:268-273
67. Camilleri M, Beyens G, Kerstens R, Vandeplassche L. Long-term follow-up safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation. Gastroenterology 2009;136:A31
68. Tack J, Dubois D, Kerstens R, et al. PAC-QOL results from 3 identical randomized placebo-controlled trials with prucalopride in patients with severe chronic constipation. Gastroenterology 2009;136:A533
69. Krobert KA, Brattelid T, Levy FO, Kaumann AJ. Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants. Naunyn Schmiedebergs Arch Pharmacol 2005;371:473-479
70. De Maeyer J, Straetemans R, Schuurkes J, Lefebvre R. Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development. Br J Pharmacol 2006;147:140-157
71. Bach T, Syversveen T, Kvingedal A, et al. 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmacol 2001;363:146-160
72. Pau D, Workman AJ, Kane KA, Rankin AC. Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists. J Pharmacol Exp Ther 2005;313:146-153
73. De Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol 2009;156:362-376
74. Walker B, Singleton C, Bursill J, et al. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 1999;128:444-450
75. Rampe D, Roy M, Dennis A, Brown A. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997;417:28-32
76. Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001;299:1007-1012
77. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007;554:98-105
78. Boyce M, Kerstens R, Beyens G, et al. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trails. Gastroenterology 2009;136:T1265
79. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-1264
80. Committee for medicinal products for human use: summary of positive opinion for Resolor. EMEA Committee for medicinal products for human use. London: EMEA/Pre-Authorisation Evaluation of Medicines for Human Use, 2009. Available from: http://www.emea. europa.eu/pdfs/human/opinion/ Resolor-44905009en.pdf. [Last accessed 27 September 2009]